My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2

Completed

• Conditions: Bladder Cancer; Neoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer
• Interventions: Drug: Atezolizumab; Drug: Trastuzumab; Drug: Vemurafenib; Drug: Vismodegib; Drug: Alectinib; Drug: Erlotinib; Drug: Pertuzumab; Drug: Cobimetinib

• Registration Number: NCT02091141
• Lead Sponsor: Genentech, Inc.

Brief Summary

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-03-17
• Study First Submitted QC: 2014-03-17
• Study First Posted: 2014-03-19
• Study Start: 2014-04-14
• Primary Completion: 2023-05-24
• Study Completion: 2023-05-24
• Results First Submitted: 2024-05-23
• Status Verified: 2024-06
• Results First Submitted QC: 2024-06-26
• Last Update Submitted: 2024-06-26
• Results First Posted: 2024-07-23
• Last Update Posted: 2024-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 673

Inclusion Criteria

• Life expectancy greater than or equal to (≥) 12 weeks
• Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
• Participants who have received standard first-line therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment
• No previous treatment with the specific assigned study drug or any other drug sharing the same target
• Measurable disease by RECIST v1.1
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 (For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment)
• Adequate hematologic, renal, and liver function as defined by the protocol
• If applicable, use of contraception methods or abstinence as defined by the protocol

Study-Drug Specific Inclusion Criteria:

Trastuzumab plus Pertuzumab

• Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2 overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer

  a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

• Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower

• Availability of an archival or new pre-treatment tissue sample is required if molecular testing was not performed by Foundation Medicine. Any available tumor tissue sample can be submitted. The tissue sample must be submitted within 4 weeks after enrollment

Erlotinib

• Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating epidermal growth factor receptor (EGFR)-activating mutations

Vemurafenib plus Cobimetinib

• Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Vismodegib

• Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1])

  a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

• All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (≤) 2 prior to starting therapy

Alectinib

• Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating anaplastic lymphoma kinase (ALK) gene rearrangements, ALK mutations, ALK copy number gain or (for melanoma only) increased ALK expression or presence of ALK-alternative transcription initiation transcript (ALKATI) a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Atezolizumab

• Molecular testing results from CLIA-certified laboratories (using tissue) demonstrating elevated tissue tumor mutational burden (tTMB ≥10 mutations/ Megabase [Mb])
• For patients where molecular testing was not performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is mandatory. For patients where molecular testing was performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is required, if available. The tissue sample must be submitted within 4 weeks after enrollment

General

Read More

Exclusion Criteria

• Participants with hematologic malignancies
• Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy ≤28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within ≤14 days
• Active or untreated brain metastases
• History of carcinomatous meningitis
• Uncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention)
• Pregnant or breastfeeding women, or intending to become pregnant during the study
• Any significant cardiovascular events within 6 months prior to study entry
• Pulmonary embolism within 30 days prior to study entry
• History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0
• Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Study-Drug Specific Exclusion Criteria:

Trastuzumab plus Pertuzumab

• Previous treatment with any HER2-targeted therapy

Erlotinib

• Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19 deletions or exon 21 L858R substitution mutations
• EGFR amplifications in the absence of EGFR-activating mutations
• Cancers with exon 20 mutations
• Previous treatment with erlotinib or any other EGFR inhibitor
• Inability to swallow pills
• Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of erlotinib

Vemurafenib plus Cobimetinib

• Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myeloma
• LVEF below institutional lower level of normal (LLN) or below 50%, whichever is lower
• History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration
• Presence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol ≥Grade 2; Hypertriglyceridemia ≥Grade 2; Hyperglycemia (fasting) ≥Grade 2; Grade ≥2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade </=1 are eligible)
• Prior or concurrent malignancy with known RAS mutation
• Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed)
• Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor
• Prior treatment with a RAF inhibitor
• Inability to swallow pills
• Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib
• History of congenital long QT syndrome or mean (average of triplicate measurements) corrected QT (QTc) measured using Fridericia's method ≥450 millisecond (ms) at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus)

Vismodegib

• Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies
• Previous treatment with vismodegib or any other hedgehog pathway inhibitor
• Inability to swallow pills
• Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib

Alectinib

• ALK-positive NSCLC, neuroblastoma, and childhood tumors
• Previous treatment with alectinib or any other ALK inhibitor
• Participants with symptomatic bradycardia
• Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib
• Inability to swallow pills
• Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of alectinib

Atezolizumab

• History of leptomeningeal disease
• Uncontrolled tumor pain
• Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed
• Uncontrolled or symptomatic hypercalcemia
• Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor
• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
• Known allergy or hypersensitivity to any component of the atezolizumab formulation
• Active or history of autoimmune disease or immune deficiency
• Prior allogeneic stem cell or solid organ transplantation
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis
• Severe infection within 4 weeks prior to initiation of study treatment
• Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
• Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab
• History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
• Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
• Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomization
• Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Atezolizumab	Atezolizumab	Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
Trastuzumab Plus Pertuzumab	Pertuzumab	Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
Trastuzumab Plus Pertuzumab	Trastuzumab	Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
Vemurafenib	Vemurafenib	Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.
Vismodegib	Vismodegib	Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
Vemurafenib Plus Cobimetinib	Vemurafenib	Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
Vemurafenib Plus Cobimetinib	Cobimetinib	Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
Alectinib	Alectinib	Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
Erlotinib	Erlotinib	Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.

Primary Outcome Measures

Name	Time	Method
Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)	From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)	The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator	From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)	The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.

Secondary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	From the date of first study treatment until disease progression as assessed by the investigator, or death from any cause, whichever occurs first (72.1 months)	PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
Percentage of Participants With Disease Control	From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)	Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
Duration of Response (DoR)	From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (70.8 months)	Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.
Overall Survival (OS)	87.5 months	Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.
Number of Participants With Adverse Events	From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years)	Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.

Trial Locations

Locations (60)

University Of Chicago Medical Center; Section Of Hematology/Oncology; 🇺🇸 Chicago, Illinois, United States

MD Anderson; 🇺🇸 Houston, Texas, United States

University of Oklahoma Health Sciences Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Tennessee Oncology - Nashville; 🇺🇸 Nashville, Tennessee, United States

Mayo Foundation; 🇺🇸 Rochester, Minnesota, United States

Providence Portland Medical Center; 🇺🇸 Portland, Oregon, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

University of Colorado; 🇺🇸 Aurora, Colorado, United States

Western Regional Medical Center at Cancer Treatment Centers of America; 🇺🇸 Goodyear, Arizona, United States

Highlands Oncology Group; 🇺🇸 Springdale, Arkansas, United States

Moores UCSD Cancer Center; Dept Clinical Trials Office; 🇺🇸 La Jolla, California, United States

Science 37, Inc; 🇺🇸 Culver City, California, United States

City of Hope Comprehensive Cancer Center; 🇺🇸 Duarte, California, United States

Eisenhower Medical Center; 🇺🇸 Rancho Mirage, California, United States

Stanford Comprehensive Cancer Center; 🇺🇸 Stanford, California, United States

Kaiser Permanente - Vallejo; 🇺🇸 Vallejo, California, United States

Mayo Clinic; 🇺🇸 Jacksonville, Florida, United States

SCRI Florida Cancer Specialists South; 🇺🇸 Fort Myers, Florida, United States

Florida Cancer Specialist, North Region; 🇺🇸 Saint Petersburg, Florida, United States

Florida Cancer Specialists, Research Department; 🇺🇸 West Palm Beach, Florida, United States

University Cancer & Blood Center, LLC; Research; 🇺🇸 Athens, Georgia, United States

Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst; 🇺🇸 Chicago, Illinois, United States

Northeast Georgia Medical Center; Oncology Research Dept-5C; 🇺🇸 Gainesville, Georgia, United States

Southeastern Regional Medical Center, Inc.; 🇺🇸 Newnan, Georgia, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 🇺🇸 Baltimore, Maryland, United States

Midwestern Regional Med Center; 🇺🇸 Zion, Illinois, United States

University of New Mexico Comprehensive Cancer Center; 🇺🇸 Albuquerque, New Mexico, United States

University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment; 🇺🇸 Albuquerque, New Mexico, United States

Memorial Sloan Kettering - Monmouth; 🇺🇸 Middletown, New Jersey, United States

San Juan Oncology Associates; 🇺🇸 Farmington, New Mexico, United States

Weill Cornell Univ Medical Ctr; Breast Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center at Westchester; 🇺🇸 Harrison, New York, United States

Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Oncology Hematology Care Inc; 🇺🇸 Cincinnati, Ohio, United States

Eastern Regional Medical Ctr; 🇺🇸 Philadelphia, Pennsylvania, United States

UPMC - Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Thomas Jefferson University Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States

Vanderbilt Ingram Cancer Clinic; 🇺🇸 Nashville, Tennessee, United States

Sanford Cancer Cnt Onco Clinic; 🇺🇸 Sioux Falls, South Dakota, United States

Sarah Cannon Research Institute / Tennessee Oncology; 🇺🇸 Chattanooga, Tennessee, United States

The Center for Cancer and Blood Disorders - Fort Worth; 🇺🇸 Fort Worth, Texas, United States

Northwest Medical Specialties; 🇺🇸 Tacoma, Washington, United States

University of Wisconsin; 🇺🇸 Madison, Wisconsin, United States

Mayo Clinic Arizona; 🇺🇸 Phoenix, Arizona, United States

Sanford Roger Maris Cancer Center; 🇺🇸 Fargo, North Dakota, United States

Abramson Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment; 🇺🇸 Albuquerque, New Mexico, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins; 🇺🇸 Willow Grove, Pennsylvania, United States

West Clinic; 🇺🇸 Germantown, Tennessee, United States

Tennessee Cancer Specialists; 🇺🇸 Knoxville, Tennessee, United States

Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch; 🇺🇸 Orlando, Florida, United States

Wake Forest Univ Health Svcs; Internal Medicine; 🇺🇸 Winston-Salem, North Carolina, United States

University Hospitals of Cleveland; 🇺🇸 Cleveland, Ohio, United States

University of New Mexico; 🇺🇸 Albuquerque, New Mexico, United States

Research Medical Center - Antibiotic Research Associates, Inc.; 🇺🇸 Kansas City, Missouri, United States

Univ No Carolina School of Med; Physicians Office Bldg; 🇺🇸 Chapel Hill, North Carolina, United States

Virginia Cancer Institute; 🇺🇸 Richmond, Virginia, United States